Literature DB >> 21753165

Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN.

J L Whitwell1, S D Weigand, J L Gunter, B F Boeve, R Rademakers, M Baker, D S Knopman, Z K Wszolek, R C Petersen, C R Jack, K A Josephs.   

Abstract

OBJECTIVE: To use multiple serial MRI to assess rates and trajectories of brain and hippocampal atrophy in subjects with frontotemporal dementia (FTD) with progranulin (GRN) or microtubule-associated protein tau (MAPT) gene mutations.
METHODS: In this case-control study, we identified 8 subjects with mutations in GRN and 12 subjects with mutations in MAPT who had at least 2 serial MRIs. Serial MRIs were registered to baseline MRI for each subject using 9 df registration and rate of whole brain atrophy was calculated using the boundary-shift integral. Hippocampal volume was measured using Freesurfer. Mixed effects linear regression models were used to model volume change over time in both groups after adjusting for head size, age at baseline, and disease duration at baseline.
RESULTS: The annual rate of whole brain atrophy in the MAPT subjects was 2.4% per year (95% confidence interval [CI] 1.9-2.8). The GRN subjects showed a higher rate of whole brain atrophy at 3.5% per year (95% CI 2.8-4.2; p = 0.01). Rates of hippocampal atrophy were not different across the groups (MAPT = 7.8% [95% CI 3.9-12], GRN = 6.5% [95% CI 1.7-11], p = 0.66). Rates of whole brain atrophy in GRN, and hippocampal atrophy in MAPT, were associated with age, with older subjects showing slower rates of atrophy (p = 0.01 and p < 0.001).
CONCLUSIONS: Subjects with FTD with GRN mutations have a faster rate of whole brain atrophy than subjects with FTD with MAPT mutations, with similar rates of hippocampal atrophy. Rates of atrophy in both groups were associated with age. These findings are important for future treatment trials in FTD that use rates of atrophy as an outcome measure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21753165      PMCID: PMC3140800          DOI: 10.1212/WNL.0b013e318227047f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Prominent phenotypic variability associated with mutations in Progranulin.

Authors:  Brendan J Kelley; Wael Haidar; Bradley F Boeve; Matt Baker; Neill R Graff-Radford; Thomas Krefft; Andrew R Frank; Clifford R Jack; Maria Shiung; David S Knopman; Keith A Josephs; Sotirios A Parashos; Rosa Rademakers; Mike Hutton; Stuart Pickering-Brown; Jennifer Adamson; Karen M Kuntz; Dennis W Dickson; Joseph E Parisi; Glenn E Smith; Robert J Ivnik; Ronald C Petersen
Journal:  Neurobiol Aging       Date:  2007-10-18       Impact factor: 4.673

2.  Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN.

Authors:  J L Whitwell; C R Jack; B F Boeve; M L Senjem; M Baker; R Rademakers; R J Ivnik; D S Knopman; Z K Wszolek; R C Petersen; K A Josephs
Journal:  Neurology       Date:  2009-03-03       Impact factor: 9.910

3.  Predicting functional decline in behavioural variant frontotemporal dementia.

Authors:  Keith A Josephs; Jennifer L Whitwell; Stephen D Weigand; Matthew L Senjem; Bradley F Boeve; David S Knopman; Glenn E Smith; Robert J Ivnik; Clifford R Jack; Ronald C Petersen
Journal:  Brain       Date:  2011-01-20       Impact factor: 13.501

4.  Rates of global and regional cerebral atrophy in AD and frontotemporal dementia.

Authors:  D Chan; N C Fox; R Jenkins; R I Scahill; W R Crum; M N Rossor
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

5.  Measuring the thickness of the human cerebral cortex from magnetic resonance images.

Authors:  B Fischl; A M Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

6.  Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations.

Authors:  J L Whitwell; C R Jack; B F Boeve; M L Senjem; M Baker; R J Ivnik; D S Knopman; Z K Wszolek; R C Petersen; R Rademakers; K A Josephs
Journal:  Neurology       Date:  2009-09-29       Impact factor: 9.910

7.  Methodological considerations for measuring rates of brain atrophy.

Authors:  Jeffrey L Gunter; Maria M Shiung; Armando Manduca; Clifford R Jack
Journal:  J Magn Reson Imaging       Date:  2003-07       Impact factor: 4.813

8.  Rates of cerebral atrophy differ in different degenerative pathologies.

Authors:  Jennifer L Whitwell; Clifford R Jack; Joseph E Parisi; David S Knopman; Bradley F Boeve; Ronald C Petersen; Tanis J Ferman; Dennis W Dickson; Keith A Josephs
Journal:  Brain       Date:  2007-03-08       Impact factor: 13.501

9.  Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations.

Authors:  Jonathan D Rohrer; Gerard R Ridgway; Marc Modat; Sebastien Ourselin; Simon Mead; Nick C Fox; Martin N Rossor; Jason D Warren
Journal:  Neuroimage       Date:  2010-01-04       Impact factor: 6.556

10.  Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations.

Authors:  Stuart M Pickering-Brown; Sara Rollinson; Daniel Du Plessis; Karen E Morrison; Anoop Varma; Anna M T Richardson; David Neary; Julie S Snowden; David M A Mann
Journal:  Brain       Date:  2008-01-11       Impact factor: 13.501

  10 in total
  25 in total

1.  Progranulin-associated PiB-negative logopenic primary progressive aphasia.

Authors:  Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Prashanthi Vemuri; Matthew L Senjem; Ralph B Perkerson; Matthew C Baker; Val Lowe; Clifford R Jack; Rosa Rademakers; Jennifer L Whitwell
Journal:  J Neurol       Date:  2014-01-22       Impact factor: 4.849

Review 2.  FTD spectrum: Neuroimaging across the FTD spectrum.

Authors:  Jennifer L Whitwell
Journal:  Prog Mol Biol Transl Sci       Date:  2019-06-18       Impact factor: 3.622

3.  Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images.

Authors:  J L Whitwell; B F Boeve; S D Weigand; M L Senjem; J L Gunter; M C Baker; M DeJesus-Hernandez; D S Knopman; Z K Wszolek; R C Petersen; R Rademakers; C R Jack; K A Josephs
Journal:  Eur J Neurol       Date:  2015-02-12       Impact factor: 6.089

Review 4.  Genetics of Frontotemporal Dementia.

Authors:  Diana A Olszewska; Roisin Lonergan; Emer M Fallon; Tim Lynch
Journal:  Curr Neurol Neurosci Rep       Date:  2016-12       Impact factor: 5.081

5.  Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study.

Authors:  Qin Chen; Bradley F Boeve; Matthew Senjem; Nirubol Tosakulwong; Timothy Lesnick; Danielle Brushaber; Christina Dheel; Julie Fields; Leah Forsberg; Ralitza Gavrilova; Debra Gearhart; Jonathan Graff-Radford; Neill Graff-Radford; Clifford R Jack; David Jones; David Knopman; Walter K Kremers; Maria Lapid; Rosa Rademakers; Eliana Marisa Ramos; Jeremy Syrjanen; Adam L Boxer; Howie Rosen; Zbigniew K Wszolek; Kejal Kantarci
Journal:  Neurobiol Aging       Date:  2019-12-12       Impact factor: 4.673

Review 6.  Recent advances in the imaging of frontotemporal dementia.

Authors:  Jennifer L Whitwell; Keith A Josephs
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

Review 7.  The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).

Authors:  Adam L Boxer; Michael Gold; Edward Huey; William T Hu; Howard Rosen; Joel Kramer; Fen-Biao Gao; Edward A Burton; Tiffany Chow; Aimee Kao; Blair R Leavitt; Bruce Lamb; Megan Grether; David Knopman; Nigel J Cairns; Ian R Mackenzie; Laura Mitic; Erik D Roberson; Daniel Van Kammen; Marc Cantillon; Kathleen Zahs; George Jackson; Stephen Salloway; John Morris; Gary Tong; Howard Feldman; Howard Fillit; Susan Dickinson; Zaven S Khachaturian; Margaret Sutherland; Susan Abushakra; Joseph Lewcock; Robert Farese; Robert O Kenet; Frank Laferla; Steve Perrin; Steve Whitaker; Lawrence Honig; Marsel M Mesulam; Brad Boeve; Murray Grossman; Bruce L Miller; Jeffrey L Cummings
Journal:  Alzheimers Dement       Date:  2012-10-10       Impact factor: 21.566

Review 8.  Neuroimaging features of C9ORF72 expansion.

Authors:  Jennifer S Yokoyama; Howard J Rosen
Journal:  Alzheimers Res Ther       Date:  2012-11-16       Impact factor: 6.982

9.  Spatiotemporal linear mixed effects modeling for the mass-univariate analysis of longitudinal neuroimage data.

Authors:  Jorge L Bernal-Rusiel; Martin Reuter; Douglas N Greve; Bruce Fischl; Mert R Sabuncu
Journal:  Neuroimage       Date:  2013-05-20       Impact factor: 6.556

10.  Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models.

Authors:  Jorge L Bernal-Rusiel; Douglas N Greve; Martin Reuter; Bruce Fischl; Mert R Sabuncu
Journal:  Neuroimage       Date:  2012-10-30       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.